Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cytomegalovirus Infections: early-phase trial registry
9 of 25 indexed Cytomegalovirus Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 9 currently recruiting · #652 of 28,707 conditions by registered trial count
Cytomegalovirus Infections: 25 US clinical trials tracked, 9 recruiting.
Cytomegalovirus Infections is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 4 of these trials.
Enrollment posture brief
Registry condition cytomegalovirus-infections
OPEN 9 | RECR 36% | LATE 6 | EARLY 14 | RANK #652 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Cannabis (36% recruiting · 25 trials)
Cytomegalovirus Infections lists 9 open slots (36% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cytomegalovirus Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cytomegalovirus Infections is recruiting below its size-band peers.
9 of 25 indexed trials (36%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Cytomegalovirus Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 4 of 25 trials (16%). 18 distinct sponsors appear on at least one study for this condition label.
-
Most Cytomegalovirus Infections trials plan to enrol fewer than 100 people.
Median target enrolment is 80 among the 25 trials that report a genuine target (sentinel values excluded). 16 of those (64%) plan for fewer than 100 participants.
-
Cytomegalovirus Infections research is mostly interventional.
21 interventional and 4 observational studies make up this index (84% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
Cytomegalovirus (CMV) Transmission and Immune Tracking (TransmIT) Study
University of Massachusetts, Worcester
NCT06522880
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
University of Wisconsin, Madison
NCT06407232
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
University of Pennsylvania
NCT06066957
R-MVST Cells for Treatment of Viral Infections
Columbia University
NCT05183490
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Tufts Medical Center
NCT05626530
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Jessie L. Alexander
NCT06909110
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
New York Medical College
NCT03266640
T Cell Therapy of Opportunistic Cytomegalovirus Infection
Mari Dallas
NCT02982902
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
NCT06926894
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation
Pediatric Transplantation & Cellular Therapy Consortium
NCT03475212
Viral Specific T-Lymphocytes to Treat Adenovirus or CMV
Jessie L. Alexander
NCT04364178
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001038
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
The Center for the Biology of Chronic Disease
NCT02715752
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
Shire
NCT00411645
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001082
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
GlaxoSmithKline
NCT05089630
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001100
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
Genentech
NCT01753167
Evaluation of the Artus® CMV PCR Test
QIAGEN Gaithersburg
NCT01034709
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05099965
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001890
Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
National Heart, Lung, and Blood Institute (NHLBI)
NCT00353977
A Study of Lobucavir in Patients With AIDS
Bristol-Myers Squibb
NCT00002352
A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine
Hoffmann-La Roche
NCT00002096
Immune Response to Cytomegalovirus
National Heart, Lung, and Blood Institute (NHLBI)
NCT00034437
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 6 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cytomegalovirus Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cytomegalovirus Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cytomegalovirus Infections page
25 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Cytomegalovirus Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most Cytomegalovirus Infections trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cytomegalovirus Infections condition card totals 25 registered trials; most-linked intervention Cytomegalovirus Specific T-Lymphocytes; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.